On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.’s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients
Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on
The World Health Organization publishes the first global guidelines to prevent the occurrence of bloodstream and other infections caused by use of catheters placed in
What does it take to help a parent avoid and manage burnout? Experts at Ohio State University came together to design a study on triggers
Heather Crivilare was a month from her due date when she was rushed to an operating room for an emergency cesarean section.
Democrat Lucas Kunce is trying to pin reproductive care restrictions on Sen. Josh Hawley (R-Mo.), betting it will boost his chances of unseating the incumbent
The long-term effects of flooding on mortality.
Addition of salt to food at the table and risk of developing stomach cancer.
Phase I clinical trial results indicated that MZE001 could become the first oral therapy option for Pompe disease. Credit: murat photographer / Shutterstock.com. Shionogi has
Assessing potential health risks of vaping e-liquid.